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Background: Children whose mothers had low thyroid hormone levels during pregnancy have been reported to
have decreased cognitive function. The reported research is part of the follow-on study of the Controlled Antenatal
Thyroid Screening Study (CATS I), a randomised controlled trial which investigated the impact of treated vs. untreated
low thyroid hormone level in women during pregnancy with the primary outcome being the child’s IQ at age 3. No
significant differences in IQ were found between the treated and untreated groups. These children are now aged
between 7 and 10 years and aspects of their cognitive functioning including their IQ are being reassessed as part
of CATS II.
Methods/Design: Cognitive assessments generate an IQ score and further tests administered will investigate
long term memory function and motor coordination. The aim is to complete the assessments with 40% of the
children born to mothers either in the treated or untreated low thyroid hormone groups (n = 120 per group).
Also children born to mothers who had normal thyroid functioning during CATS I are being assessed for the first
time (n = 240) to provide a comparison. Assessments are conducted either in the research facility or the participant’s
home.
Discussion: The study is designed to assess the cognitive functioning of children born to mothers with low thyroid
hormone levels and normal thyroid functioning during pregnancy. This is the largest study of its type and also is
distinguishable in its longitudinal design. The research has the potential to have a significant impact on public
health policy in the UK; universal screening of thyroid hormone levels in pregnancy may be the recommendation.
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Thyroid functionBackground
Subclinical Hypothyroidism (SH), defined as an elevated
level of thyroid stimulating hormone (TSH) with normal
circulating levels of free thyroxine (T4) and free tri-
iodothyronine (T3) [1], affects 3-6% of the UK population
[2,3]. SH in pregnancy is defined as a TSH concentration
higher than the upper limit of the pregnancy related
reference-range with normal T4 (and, if measured, normal
T3). The upper limit of TSH is now defined as 2.5 mIU/l* Correspondence: halesc2@cardiff.ac.uk
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unless otherwise stated.in the first trimester and 3 mIU/l in the second and third
trimesters [4,5]. SH is a biochemical diagnosis as symp-
toms may be mild, non-specific and mimic typical symp-
toms occurring in pregnancy [6]. The recent lowering of
the pregnancy TSH threshold has had a dramatic effect
on the prevalence of Gestational SH (GSH) with preva-
lence rates in Belgium increasing from 2-3% to 6.8% [7]
and over 15% in a recent large pregnancy screening study
in the USA [8].
Iodine is an essential component of thyroid hormones
and the UK population is borderline iodine deficient [9].
When iodine supplies are severely inadequate, TSH in-
creases as a compensation mechanism. In women withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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iodine stores are not able to compensate for increased iod-
ine demands leading to increased risk of maternal goitre
and hypothyroidism [10].
There is some evidence that neuropsychological and
intellectual development of offspring can be adversely af-
fected by an iodine deficiency during pregnancy [11-13]
or GSH [14-18]. Intellect, as measured by Intelligence
Quotient (IQ) tests has been shown to predict a range of
life outcomes such as academic performance, job perform-
ance, years in education and even physical health [19-25].
The suggested mechanism for these effects of iodine defi-
ciency and GSH is that although the brain is very dependent
on thyroid hormones for normal development, active
secretion of thyroid hormone in the fetus does not start
until about 18-20 weeks gestation so the fetus is dependent
on the mothers’ circulating hormones for growth and
development up until this point [26]. The number of
studies investigating the impact of an untreated GSH
on an offspring’s IQ is growing but the findings are
equivocal: in one retrospective study untreated GSH was
shown to lower an offspring’s IQ by a mean of 7 points
[14], and out of the 48 GSH offspring compared to 124
matched control children, 19% of these had an IQ of <85
compared to only 5% of the controls (IQ scores as mea-
sured on standardised tests are normally distributed so an
average IQ score falls in the range of 90-109; with a per-
centile ranking of 50 for an IQ of 100).
Further studies have also shown a deficit of GSH hav-
ing an impact on the offspring’s intelligence [14,27-29].
Li [15] detected this impact on children as young as 25-
30 months (compared to controls, mean intelligence scores
were found to be significantly lower p = 0.008). There is
also some evidence of more specific impairments to the
offspring; motor coordination, attention, language and
visuo-motor performance [14,15,29-31]. However other
research, including prospective studies, have not found
that GSH affects any aspect of cognition for the offspring
[17,32,33].
If there is a significant impact of GSH on the child’s
development, this could potentially be widespread and
to test and treat for GSH is reasonably “low-cost” [34].
In response to these findings of an effect there are those
who propose screening during pregnancy to help deter-
mine the circulating thyroid hormone levels in the mothers
[34,35]. However before that decision can be made the
evidence needs to be more robust based on longitudinal
large-scale randomised trials including women with treated
and untreated GSH and their off-spring. The Controlled
Antenatal Thyroid Screening (CATS) study is one such
trial, understood to be the largest randomised controlled
trial (RCT) of this kind to date.
Between 2002 and 2006 the CATS I study [36] recruited
participants in the UK (10 centres) and Italy (1 centre:Turin). A total of 16,349 pregnant women with no known
thyroid disease participated in the UK at a gestation of
16 weeks or less and a blood sample was obtained to
measure TSH and T4 (A further 5,497 were recruited in
Turin and included in CATS I but are not being included
in this follow-on study; CATS II). TSH levels above the
97.5th percentile, free T4 levels below the 2.5th percentile,
or both were considered as a Suboptimal Gestational
Thyroid Function (SGTF) result. Women with SGTF in
the screen group were treated during their pregnancy
and those in the control group with SGTF were untreated
(see article Lazarus [36] for further details). IQ of the off-
spring was measured at a mean age of 3.2 years with no
significant differences found between the groups.
Whilst measuring IQ at age 3 has value as a general
indicator of cognitive function, it does not give a detailed
cognitive profile. It is not best suited as a longer term esti-
mation of cognition function [37] which can be achieved
by administering a more in-depth battery of assessments
with older children. Therefore the primary aim of CATS II
is to measure the children’s cognitive function at age 7–10
years. In addition to the cognitive assessments the study
has expanded to include investigations of (i) the child and
mothers’ bone mineral density (ii) height, waist and weight
measurements, blood pressure and arterial stiffness (iii)
DNA collection (iv) and behavioural questionnaires. The
outline of these additional investigations will be included
but the details are outside the range of this protocol which
focuses on the primary outcome; the child's cognitive
functioning.Methods
CATS II is a follow-on study from CATS I, a large multi-
centre RCT, that aims to investigate the possible long term
effects of exposure to SGTF. Cognitive assessments are
administered to children aged between 7 and 10 years to
ascertain their overall development. The study is aiming
to recruit a total of 480 participants between August 2011
and the end of August 2015. Participants can be seen in
either the research centre or can choose to be visited in
their homes. If the participants prefer they can opt to pro-
vide a reduced data set using a post pack. The study was
approved by the Wales Research Ethics Committee 2 and
Caldicott Guardian.Eligibility
Participants are included if they were involved in
CATS I and originally recruited from the UK, and are
approached for CATS II when the child involved in
the study is ≥7 years 0 months to ≤ 10 years 11 months.
Participants are excluded from the study if they have
moved overseas.
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With a 5% two-sided significance level and 90% power, a
sample of 120 from both treated and untreated SGTF
groups will allow a detection of a difference of 6 IQ points
in mean IQ (assuming mean IQ to be 100 with a standard
deviation (SD) of 15 points) [38].
We have used an increase in the odds of IQ < 85 as a
primary outcome in treated and untreated SGTF groups,
similar to the CATS I analysis. We have 80% power with
a 5% two-sided significance level to detect a 1.97 increase
in odds of IQ < 85 in untreated SGTF offspring assuming
treated SGTF offspring have a mean IQ of 100 with a SD
of 15. This is substantially lower odds than that observed
comparing low thyroid hormone bioavailability to those
offspring of mothers with normal GTF bioavailability
(odds ratio = 2.36). In addition 240 participants (1.5%)
from the normal GTF group who are randomly selected
from the complete group of 15,744 from the UK cohort
will be used to assess whether there is interaction with
maternal thyroid status and levothyroxine treatment on
offspring IQ.
Recruitment
An initial contact pack inviting the CATS I mothers to
participate in the research is mailed to all in the SGTF
groups. Re-involvement in to CATS is centred on the
age of the child; those born earliest during CATS I are
contacted first in a rolling recruitment process over theEligible CATS
approa
Recruitment pack 
process based on
Response form r
participant in
prefer
1)  Request 
further 
information
2) Post pack
DNA
Questionnaires
Data Collected
Figure 1 CATS II recruitment process.48 months of the project. The Welsh Demographics
Service and Patient Data Registrar have been utilised to
ensure up-to-date addresses for individuals from the
SGTF groups. Figure 1 details the recruitment process
for participants.
Those participants, who wish to complete the cognitive
assessments at their home or by attending the research
centre, are contacted to arrange the appointment and post
packs are mailed out. Research centre appointments take
2.5 hours, home appointments last for 2 hours or less.
A different letter is sent to individuals from the normal
GTF group who consented to participate in CATS I but
did not participate in the cognitive assessments. There are
15,744 potential participants that could be contacted from
the Wales CATS I cohort for re-involvement into CATS
II. 240 participants are required from this group for CATS
II. As participants are contacted by year of registration
into the study a random selection is mailed from each of
the 4 years CATS I recruited for, totalling 5,000 packs
being sent to mothers from the normal GTF group.
Cognitive measures and procedure
To be able to address the primary aim of CATS II, an IQ
test (1) and additional cognitive tasks (2) are administered
to the children in the study.
1. The Wechsler Intelligence Scale for Children- Fourth
Edition UK (WISC). The WISC [38] provides sub-test I participants 
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functioning across specific cognitive domains: Verbal
Comprehension (VC); Perceptual Reasoning (PR);
Working Memory (WM); and Processing Speed (PS).
The IQs generated from these areas equally contribute
to the Full Scale (FS) IQ.
2. Developmental NEuroPSYchological Assessment-
Second Edition (NEPSY). Possible delays in long
term memory (LTM), WM and fine-motor skills are
investigated by sub-tests from the NEPSY [39]: List
Memory and List Memory Delayed (combined
score) (LTM), Memory for Designs (WM), Memory
for Designs Delayed (LTM), Fingertip Tapping
(motor) and Narrative Memory (WM).
If the participants opt to attend the research centre,
the child is assessed in a clinical environment. If partici-
pants select to be seen at their homes, a table and a
quiet room with minimal distractions are requested. The
tests are administered in a set order with standardised
verbal instructions given to each child. The WISC is ad-
ministered first, followed by the NEPSY.
The WISC raw scores are calculated by hand; an auto-
mated WISC scorer software is then used to calculate the
scaled and composite scores and generate a report for
the parents. This details the composite scores, percentile
ranks and classifications (e.g. average, high average etc.) of
the FSIQ, VCIQ, PRIQ, WMIQ and the PSIQ. If the partici-
pants have any questions regarding their child’s results, they
are able to directly contact the examiner (a psychologist)
who completed the assessments.
There is only one examiner on the project to increase
reliability. Training was completed for cognitive test ad-
ministration. A randomly selected 10% of the completed
assessments are double scored to ensure reliability. Means
are reviewed fortnightly to ensure no scaled or composite
scores are well above or below the average which may in-
dicate skewed testing. There is also an ongoing evaluation
of age and gender distribution between normal GTF and
the SGTF groups.
Statistical analysis
The main statistical analysis will be executed according
to the CATS II analysis plan. The data will be analysed
using STATA version 12. Dataset accuracy will be scruti-
nised using histograms and cross tabulations to identify
any outliers and errors in the data set. Implausible values
(>4 SD from the mean) will be considered as outliers
and will be recoded as ‘missing’. Descriptive statistics
will be presented as means, SD, medians and lower and
upper quartiles. All variables will be standardized; ana-
lyses will therefore be presented as per SD, for linear
regression analysis. Odds ratios will be assessed for FSIQ
thresholds.Primarily, a univariable analysis will be commenced
followed by subsequent multivariate analyses to adjust
for key potential confounders relating to schooling and
social class. Logistic regression will be used to identify
if untreated SGTF offspring have increased odds of an
FSIQ < 85 compared to treated SGTF offspring. Children
of normal GTF mothers will be included in a secondary
analysis to assess the odds of an FSIQ <85 by maternal
thyroid status; with an interaction term for treatment sta-
tus to enable us to see if treatment reduces the risk of low
FSIQ.
The following four models of analysis will be used to
explore the data;
a. Model 1; Crude
b. Model 2; adjusted for child sex
c. Model 3; adjusted for model 2 and age of mothers at
birth of offspring and whether the child was
breastfed.
d. Model 4; adjusted for model 3 and schooling (Welsh
or English school attended) and socioeconomic
background.
The primary analysis for the study is assessing the
odds of FSIQ below 85 in children of mothers who had
SGTF compared to children of mothers with normal
GTF, calculated by a logistic regression. An interaction
term will be included for treatment vs. no treatment.
This outcome will therefore utilise our entire CATS II
cohort and is similar to CATS I in that it also investi-
gates FSIQ 1 SD from the mean.
Secondary analysis outcomes specific to the cognitive
data collection will investigate multiple aspects. Firstly, we
will explore whether children from the untreated SGTF
groups have an increased odds of a VCIQ <85 and if their
LTM and motor coordination is significantly lower than
offspring from mothers with treated SGTF. Secondly, we
will investigate if there is evidence of non-proportional
odds of a lower FSIQ in children of treated compared to
untreated SGTF mothers’ using likelihood ratio tests on
generalized ordered logistic thresholds to assess if the data
best fits a proportional or non-proportional model. Fur-
thermore, by applying data from our offspring of normal
GTF mothers, we can explore the odds of this group hav-
ing a higher FSIQ than children of treated SGTF mothers;
this will include a non-inferiority analysis. Likewise, by
comparing the normal GTF to the untreated SGTF data,
we can investigate whether maternal TSH predicts FSIQ.
Additionally, we can investigate whether maternal TSH
and poor DIO2 (a gene involved in activating T4 to T3) in
the offspring predicts FSIQ; this gene will be genotyped in
CATS’ children using standard protocols. This final
secondary analysis will use data from the normal GTF
and untreated SGTF groups and from this we could
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having lower FSIQ.
Final investigations of the cognitive data will take the
form of a sensitivity analysis. CATS I and CATS II VCIQ,
PRIQ and FSIQs can all be compared; which will assist
identifying whether there is any bias found in CATS II in
relation to those participants recruited to CATS I. The
WISC utilises scaled scores to calculate IQs, and the
NEPSY also reports scaled scores. Therefore compari-
sons between the WISC WM scores can be compared
to the NESPY WM scores. Finally, an imperative sensi-
tivity analysis will look at the extent to which offspring
of mothers whom had normal GTF represent a normal
population i.e. IQs at a mean of 100 and NEPSY scaled
scores at a mean of 10 for each subtest.
Discussion
The aim of this paper is to describe the study protocol
of the cognitive aspects of the CATS II research project.
By conducting this study, we hope to better understand
the impact of maternal hypothyroidism and whether treat-
ment for such should be sought. We will add to the wider
literature for SGTF and contribute to knowledge in clin-
ical, epidemiology and psychology fields. The current re-
search is, to the authors’ knowledge, the largest of its kind
in the world to have a treated compared to untreated
model of SGTF at this age group; it has the potential to
have a significant impact in the UK and may be policy
changing; universal screening for SGTF may be the out-
come based on the study recommendations. If treatment
for SGTF is found to have an impact on FSIQ, it is our
aim to revisit these children to repeat assessments at
age ≥14 years. CATS II recruits when the children are
aged between 7–10 years; one of these reasons being
that IQ discrepancies of offspring of normal GTF and
hypothyroid mothers during pregnancy, were identified
in children aged 7 [14]. A further reason for assessing
children at this age is related to our further investiga-
tions for CATS II; specifically the bone mineral density
measurements, these should be taken before the con-
founding factors of puberty occur.
The key strength of this study is assessing the offspring
at a second time point during their lives. We are not aware
of any other studies in this field that have completed this.
By being flexible in our outcome measurements for the
participants, we are able to maximise recruitment. A fur-
ther strength is the volume of data collected; bone density,
DNA samples, child behavioural questionnaires are just
some of the data the participants will provide. The main
challenge of this study will be the recruitment targets and
the rate of attrition. A biased sample in the normal GTF
group may present itself; individuals better equipped to
aid the study, for example with free time will more readily
volunteer. This bias may only present in the normal GTFgroup, as those from the SGTF groups took part more
recently (when the child was aged 3.2) and are more
likely to remember their participation.
In summary, CATS II is a follow-on study from a large
RCT collecting a wealth of data with the primary aim of
investigating FSIQ of offspring born to mothers who had
SGTF compared to those with mothers who had normal
GTF. Regardless of outcome, the results will have an effect
of how an underactive thyroid during pregnancy is per-
ceived, and more importantly, whether it is imperative to
treat or not.
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